person · Reporting owner

NABEL ELIZABETH G

Disclosed activity across 8 companies

Tapewire entity: 38776
SEC CIK: 0001619929

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Lyell Immunopharma, Inc.LYEL · Entity 5757	Director	June 10, 2025	June 12, 2026
Medtronic plcMDT · Entity 2888	Director	April 27, 2026	April 29, 2026
Moderna, Inc.MRNA · Entity 2025	Director	May 06, 2026	May 08, 2026
abrdn Healthcare InvestorsHQH · Entity 8816	Director	December 13, 2018	December 19, 2018
abrdn Healthcare Opportunities FundTHQ · Entity 5102	Director	December 13, 2018	December 19, 2018
abrdn Life Sciences InvestorsHQL · Entity 8835	Director	December 13, 2018	December 19, 2018
abrdn World Healthcare FundTHW · Entity 5390	Director	December 13, 2018	December 19, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Lyell Immunopharma, Inc.

Report date June 10, 2025 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.22 · Expires 2036-06-09	Direct	9,250	Reported balance After 2026-06-10 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-06-10 · Grant · Acquired 9,250 · Balance 9,250 F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date.

Medtronic plc

Report date April 27, 2026 · Filed April 29, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	19,791	Reported balance After 2026-04-27 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-04-27 · Grant · Acquired 2,111 · Balance 19,791 F1: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person.
Ordinary SharesSEC Table I · non-derivative	Direct	19,584	Reported balance After 2026-04-28 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-04-28 · Tax withholding · Disposed 207 · Balance 19,584 F3: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an award of restricted stock units that vest on the one-year anniversary of the award date.

F2: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person.

F3: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I.

Moderna, Inc.

Report date May 06, 2026 · Filed May 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	8,371	Reported balance After 2026-05-06 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-06 · Grant · Acquired 8,371 · Balance 8,371 F1: Restricted stock units convert into common stock on a one-for-one basis. F2: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service.

abrdn Healthcare Investors

Report date December 13, 2018 · Filed December 19, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Shares of Beneficial InterestSEC Table I · non-derivative	Direct	2,417	Reported balance Holding disclosure · report date 2018-12-13 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,417

abrdn Healthcare Opportunities Fund

Report date December 13, 2018 · Filed December 19, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Shares of Beneficial InterestSEC Table I · non-derivative	Direct	2,816	Reported balance Holding disclosure · report date 2018-12-13 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,816

abrdn Life Sciences Investors

Report date December 13, 2018 · Filed December 19, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Shares of Beneficial InterestSEC Table I · non-derivative	Direct	2,787	Reported balance Holding disclosure · report date 2018-12-13 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 2,787

abrdn World Healthcare Fund

Report date December 13, 2018 · Filed December 19, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Shares of Beneficial InterestSEC Table I · non-derivative	Direct	3,799	Reported balance Holding disclosure · report date 2018-12-13 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 3,799

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Accolade, Inc.

Report date April 08, 2025 · Filed April 08, 2025

Section 16 reporting ended · disclosed 2025-04-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-04-08 transaction · row 1 1 source row Row 1 · 2025-04-08 · Disposition to issuer · Disposed 41,982 · Balance 0 F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2025, by and among Issuer, Transcarent, Inc. ("Parent") and Acorn Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on April 8, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $7.03 in cash, without interest (the "Merger Consideration").
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-04-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-04-08 · Disposition to issuer · Disposed 35,021 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. RSUs convert into the Issuer's Common Stock on a one-for-one basis. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the Effective Time that is vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a "Vested Company RSU") and restricted stock units outstanding immediately prior to the Effective Time that vest, or become eligible to vest, based on the achievement of performance conditions and that are vested or that will become vested as of immediately prior to the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a "Vested Company PSU") will be cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholdings. F3: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 6, 2025 (the one year anniversary of the 2024 annual meeting date), subject to continued service as a director through each applicable vesting date.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-04-08 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-04-08 · Disposition to issuer · Disposed 12,489 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. RSUs convert into the Issuer's Common Stock on a one-for-one basis. F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the Effective Time that is vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a "Vested Company RSU") and restricted stock units outstanding immediately prior to the Effective Time that vest, or become eligible to vest, based on the achievement of performance conditions and that are vested or that will become vested as of immediately prior to the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a "Vested Company PSU") will be cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholdings. F5: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2025 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2025, by and among Issuer, Transcarent, Inc. ("Parent") and Acorn Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on April 8, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $7.03 in cash, without interest (the "Merger Consideration").

F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. RSUs convert into the Issuer's Common Stock on a one-for-one basis.

F3: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 6, 2025 (the one year anniversary of the 2024 annual meeting date), subject to continued service as a director through each applicable vesting date.

F4: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the Effective Time that is vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a "Vested Company RSU") and restricted stock units outstanding immediately prior to the Effective Time that vest, or become eligible to vest, based on the achievement of performance conditions and that are vested or that will become vested as of immediately prior to the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a "Vested Company PSU") will be cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholdings.

F5: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2025 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 10, 2026 Filed Jun 12, 2026 20:22 UTC	Lyell Immunopharma, Inc. LYEL · Entity 5757	GrantOption (right to buy) · Derivative	9,250	$0.00 Strike: $13.22	$0.00	Disclosure SEC source: 0001619929-26-000004 · form4-06122026_080608.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,250 Underlying: Common Stock · 9,250 shares Expires 2036-06-09 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 10, 2026 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 10, 2026, subject to the Reporting Person providing continuous service through such date. Read SEC document
May 06, 2026 Filed May 8, 2026 21:02 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	8,371	$0.00	$0.00	Disclosure SEC source: 0001682852-26-000091 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,371 Underlying: Common Stock · 8,371 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2027, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document
April 30, 2026 Filed May 4, 2026 20:59 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionRestricted Stock Units · Derivative	16,233	$0.00	$0.00	Disclosure SEC source: 0001682852-26-000066 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,233 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2026. Read SEC document
April 30, 2026 Filed May 4, 2026 20:59 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionCommon Stock	16,233	Not disclosed	Not disclosed	Disclosure SEC source: 0001682852-26-000066 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
April 28, 2026 Filed Apr 29, 2026 20:17 UTC	Medtronic plc MDT · Entity 2888	Tax withholdingOrdinary Shares	207	$81.90	$16,953.30	Disclosure SEC source: 0001619929-26-000002 · wk-form4_1777493842.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,584 F3 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. Read SEC document
April 27, 2026 Filed Apr 29, 2026 20:17 UTC	Medtronic plc MDT · Entity 2888	GrantOrdinary Shares	2,111	$0.00	$0.00	Disclosure SEC source: 0001619929-26-000002 · wk-form4_1777493842.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,791 F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2 · balance_after: Includes 65 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document
May 15, 2025 Filed May 19, 2025 22:43 UTC	Lyell Immunopharma, Inc. LYEL · Entity 5757	GrantOption (right to buy) · Derivative	130,000	$0.00 Strike: $0.40	$0.00	Disclosure SEC source: 0001415889-25-013707 · form4-05192025_100536.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-05-14 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following May 15, 2025 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of May 15, 2025, subject to the Reporting Person providing continuous service through such date. Read SEC document
April 30, 2025 Filed May 1, 2025 20:30 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	16,233	$0.00	$0.00	Disclosure SEC source: 0001127602-25-012938 · form4.xml · derivative · entry 3 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,233 Underlying: Common Stock · 16,233 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. F3 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 30, 2026, or Moderna's next Annual Meeting of Shareholders, subject to the recipient's continued service. Read SEC document
April 30, 2025 Filed May 1, 2025 20:30 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionRestricted Stock Units · Derivative	979	$0.00	$0.00	Disclosure SEC source: 0001127602-25-012938 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 979 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 30, 2025. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 30, 2025. Read SEC document
April 30, 2025 Filed May 1, 2025 20:30 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionCommon Stock	979	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-012938 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,084 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
April 29, 2025 Filed Apr 30, 2025 20:20 UTC	Medtronic plc MDT · Entity 2888	Tax withholdingOrdinary Shares	216	$84.60	$18,273.60	Disclosure SEC source: 0001613103-25-000069 · wk-form4_1746044411.xml · nonDerivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,615 F3 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. Read SEC document
April 28, 2025 Filed Apr 30, 2025 20:20 UTC	Medtronic plc MDT · Entity 2888	GrantOrdinary Shares	2,083	$84.04	$175,055.32	Disclosure SEC source: 0001613103-25-000069 · wk-form4_1746044411.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,831 F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2 · balance_after: Includes 74 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document
April 08, 2025 Filed Apr 8, 2025 10:21 UTC	Accolade, Inc. ACCD · Entity 80959	Disposition to issuerRestricted Stock Units · Derivative	12,489	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-010340 · form4-04082025_020441.xml · derivative · entry 3 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,489 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. RSUs convert into the Issuer's Common Stock on a one-for-one basis. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the Effective Time that is vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a "Vested Company RSU") and restricted stock units outstanding immediately prior to the Effective Time that vest, or become eligible to vest, based on the achievement of performance conditions and that are vested or that will become vested as of immediately prior to the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a "Vested Company PSU") will be cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholdings. F5 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2025 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F5 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2025 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
April 08, 2025 Filed Apr 8, 2025 10:21 UTC	Accolade, Inc. ACCD · Entity 80959	Disposition to issuerRestricted Stock Units · Derivative	35,021	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-010340 · form4-04082025_020441.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,021 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. RSUs convert into the Issuer's Common Stock on a one-for-one basis. F4 · price: Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the Effective Time that is vested, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee, (each, a "Vested Company RSU") and restricted stock units outstanding immediately prior to the Effective Time that vest, or become eligible to vest, based on the achievement of performance conditions and that are vested or that will become vested as of immediately prior to the Effective Time, after giving effect to any applicable vesting acceleration and separation right applicable to any individual other than a continuing employee (each, a "Vested Company PSU") will be cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholdings. F3 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 6, 2025 (the one year anniversary of the 2024 annual meeting date), subject to continued service as a director through each applicable vesting date. F3 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 6, 2025 (the one year anniversary of the 2024 annual meeting date), subject to continued service as a director through each applicable vesting date. Read SEC document
April 08, 2025 Filed Apr 8, 2025 10:21 UTC	Accolade, Inc. ACCD · Entity 80959	Disposition to issuerCommon Stock	41,982	$7.03	$295,133.46	Disclosure SEC source: 0001415889-25-010340 · form4-04082025_020441.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition of the Issuer's equity securities upon the consummation of the transactions contemplated by the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2025, by and among Issuer, Transcarent, Inc. ("Parent") and Acorn Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), including the consummation of the merger (the "Merger") between Issuer and Merger Sub on April 8, 2025. Pursuant to the Merger Agreement, as of the effective time of the Merger (the "Effective Time"), each share of the Issuer's Common Stock, par value $0.0001 per share ("Shares") issued and outstanding immediately prior to the Effective Time was converted automatically into the right to receive $7.03 in cash, without interest (the "Merger Consideration"). Read SEC document
March 03, 2025 Filed Mar 5, 2025 12:57 UTC	Accolade, Inc. ACCD · Entity 80959	GrantRestricted Stock Units · Derivative	12,489	$0.00	$0.00	Disclosure SEC source: 0001127602-25-008236 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,489 Underlying: Common Stock · 12,489 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2025 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F2 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2025 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
February 28, 2025 Filed Mar 4, 2025 11:08 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	2,178	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-007668 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,178 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
February 28, 2025 Filed Mar 4, 2025 11:08 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	2,178	$0.00	$0.00	Disclosure SEC source: 0001127602-25-007668 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,982 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of Common Stock upon vesting of the RSU. Read SEC document
December 02, 2024 Filed Dec 4, 2024 11:00 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	2,179	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-028585 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,178 Underlying: Common Stock · 2,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
December 02, 2024 Filed Dec 4, 2024 11:00 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	2,179	$0.00	$0.00	Disclosure SEC source: 0001127602-24-028585 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document
September 03, 2024 Filed Sep 5, 2024 09:39 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	2,179	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-023514 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,357 Underlying: Common Stock · 2,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
September 03, 2024 Filed Sep 5, 2024 09:39 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	2,179	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-023514 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document
August 06, 2024 Filed Aug 8, 2024 14:20 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	9,196	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-021873 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,196 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 8, 2024 (the one year anniversary measured from the 2023 annual meeting date), each subject to continued service as a director through each applicable vesting date. F3 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 8, 2024 (the one year anniversary measured from the 2023 annual meeting date), each subject to continued service as a director through each applicable vesting date. Read SEC document
August 06, 2024 Filed Aug 8, 2024 14:20 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	9,196	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-021873 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document
August 06, 2024 Filed Aug 8, 2024 14:01 UTC	Accolade, Inc. ACCD · Entity 80959	GrantRestricted Stock Units · Derivative	35,021	$0.00	$0.00	Disclosure SEC source: 0001127602-24-021857 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,021 Underlying: Common Stock · 35,021 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 6, 2025 (the one year anniversary of the 2024 annual meeting date), subject to continued service as a director through each applicable vesting date. F2 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 6, 2025 (the one year anniversary of the 2024 annual meeting date), subject to continued service as a director through each applicable vesting date. Read SEC document
June 14, 2024 Filed Jun 17, 2024 20:09 UTC	Lyell Immunopharma, Inc. LYEL · Entity 5757	GrantOption (right to buy) · Derivative	130,000	$0.00 Strike: $2.36	$0.00	Disclosure SEC source: 0001415889-24-017152 · form4-06172024_080605.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2034-06-13 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 14, 2024 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 14, 2024, subject to the Reporting Person providing continuous service through such date. Read SEC document
May 31, 2024 Filed Jun 3, 2024 09:00 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	2,179	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-017163 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,536 Underlying: Common Stock · 2,179 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
May 31, 2024 Filed Jun 3, 2024 09:00 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	2,179	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-017163 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document
May 06, 2024 Filed May 7, 2024 20:48 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	979	$0.00	$0.00	Disclosure SEC source: 0001127602-24-014456 · form4.xml · derivative · entry 4 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 979 Underlying: Common Stock · 979 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F4 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
May 06, 2024 Filed May 7, 2024 20:48 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	5,668	$0.00 Strike: $122.13	$0.00	Disclosure SEC source: 0001127602-24-014456 · form4.xml · derivative · entry 3 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,668 Underlying: Common Stock · 5,668 shares Expires 2034-05-06 F3 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
May 03, 2024 Filed May 7, 2024 20:48 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionRestricted Stock Units · Derivative	732	$0.00	$0.00	Disclosure SEC source: 0001127602-24-014456 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on May 3, 2024. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on May 3, 2024. Read SEC document
May 03, 2024 Filed May 7, 2024 20:48 UTC	Moderna, Inc. MRNA · Entity 2025	Exercise / conversionCommon Stock	732	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-014456 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document
May 01, 2024 Filed May 3, 2024 17:10 UTC	Medtronic plc MDT · Entity 2888	Tax withholdingOrdinary Shares	192	$80.89	$15,530.88	Disclosure SEC source: 0001613103-24-000052 · wk-form4_1714756240.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,674 F1 · shares: Represents shares withheld for payment of taxes upon the vesting of restricted stock units previously reported on Table I. Read SEC document
April 29, 2024 Filed May 1, 2024 21:15 UTC	Medtronic plc MDT · Entity 2888	GrantOrdinary Shares	2,165	$80.86	$175,061.90	Disclosure SEC source: 0001613103-24-000034 · wk-form4_1714598113.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,866 F1 · shares: Represents an award of restricted stock units that vest on the one-year anniversary of the award date. F2 · balance_after: Includes 66 shares acquired through dividend reinvestment since the last report filed by the reporting person. Read SEC document
March 01, 2024 Filed Mar 5, 2024 09:32 UTC	Accolade, Inc. ACCD · Entity 80959	GrantRestricted Stock Units · Derivative	8,715	$0.00	$0.00	Disclosure SEC source: 0001127602-24-008327 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,715 Underlying: Common Stock · 8,715 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F2 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2024 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
February 29, 2024 Filed Mar 4, 2024 09:06 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	1,751	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-007979 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
February 29, 2024 Filed Mar 4, 2024 09:06 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	1,751	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-24-007979 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document
November 30, 2023 Filed Dec 4, 2023 13:55 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	1,751	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-028679 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,751 Underlying: Common Stock · 1,751 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
November 30, 2023 Filed Dec 4, 2023 13:55 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	1,751	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-028679 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document
September 08, 2023 Filed Sep 8, 2023 20:23 UTC	Lyell Immunopharma, Inc. LYEL · Entity 5757	GrantOption (right to buy) · Derivative	55,000	$0.00 Strike: $3.19	$0.00	Disclosure SEC source: 0001209191-23-048783 · doc4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-09-07 F1 · security: On September 6, 2023, to align with benchmarking data, the issuer's Compensation Committee amended the Non-Employee Director Compensation Policy to increase the annual equity grant to non-employee directors. The Reporting Person was granted an option to purchase 65,000 shares on June 16, 2023, prior to the amendment of the policy. This additional option grant aligns the Reporting Person's total 2023 grants with the updated policy. F2 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be re-elected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date. Read SEC document
August 31, 2023 Filed Aug 31, 2023 15:11 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	1,752	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-023465 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,502 Underlying: Common Stock · 1,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
August 31, 2023 Filed Aug 31, 2023 15:11 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	1,752	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-023465 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,569 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document
August 18, 2023 Filed Aug 22, 2023 15:27 UTC	Accolade, Inc. ACCD · Entity 80959	GrantRestricted Stock Units · Derivative	9,196	$0.00	$0.00	Disclosure SEC source: 0001127602-23-023055 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,196 Underlying: Common Stock · 9,196 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 8, 2024 (the one year anniversary measured from the 2023 annual meeting date), each subject to continued service as a director through each applicable vesting date. F2 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) August 8, 2024 (the one year anniversary measured from the 2023 annual meeting date), each subject to continued service as a director through each applicable vesting date. Read SEC document
July 25, 2023 Filed Jul 27, 2023 14:49 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	14,060	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-021387 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,060 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. F3 · derivative.expiration_date: The shares subject to the RSU will vest on the earlier of (i) the date of the following annual meeting of the Issuer's stockholders (or the date immediately prior to the next annual meeting of the Issuer's stockholders if the Reporting Person's service as a director ends at such meeting due to the Reporting Person's failure to be re-elected or the director not standing for re-election) or (ii) the one year anniversary measured from the date of grant, each subject to continued service as a director through each applicable vesting date. Read SEC document
July 25, 2023 Filed Jul 27, 2023 14:49 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	14,060	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-021387 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of the Issuer's common stock. Read SEC document
June 16, 2023 Filed Jun 20, 2023 20:47 UTC	Lyell Immunopharma, Inc. LYEL · Entity 5757	GrantOption (right to buy) · Derivative	65,000	$0.00 Strike: $3.19	$0.00	Disclosure SEC source: 0001209191-23-038441 · doc4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2033-06-15 F1 · derivative.exercise_date: The option shares shall vest on the earlier of (a) the date of the next annual meeting of the stockholders that occurs following June 16, 2023 (or the date immediately prior to such date if the Reporting Person's service as a director ends at such annual meeting due to the Reporting Person's failure to be reelected or the Reporting Person not standing for re-election); or (b) the first anniversary of June 16, 2023, subject to the Reporting Person providing continuous service through such date. Read SEC document
May 31, 2023 Filed Jun 1, 2023 16:00 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionRestricted Stock Units · Derivative	1,752	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-017338 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,254 Underlying: Common Stock · 1,752 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F2 · price: Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting of the RSU. F3 · derivative.exercise_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: The shares subject to this RSU shall vest at a rate of twenty-five percent of the total number of shares on the last day of each quarter following March 1, 2023 (the "Vesting Commencement Date") for so long as the recipient of the RSU provides Continuous Service to the Issuer, such that the total number of shares shall be fully vested on the one-year anniversary of the Vesting Commencement Date. Read SEC document
May 31, 2023 Filed Jun 1, 2023 16:00 UTC	Accolade, Inc. ACCD · Entity 80959	Exercise / conversionCommon Stock	1,752	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-23-017338 · form4.xml · nonDerivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") converted into one share of Common Stock upon vesting of the RSU. Read SEC document
May 03, 2023 Filed May 5, 2023 20:13 UTC	Moderna, Inc. MRNA · Entity 2025	GrantRestricted Stock Units · Derivative	732	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-23-014679 · form4.xml · derivative · entry 2 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732 Underlying: Common Stock · 732 shares Expires not disclosed F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document
May 03, 2023 Filed May 5, 2023 20:13 UTC	Moderna, Inc. MRNA · Entity 2025	GrantStock Option (Right to Buy) · Derivative	4,601	$0.00 Strike: $130.14	$0.00	Disclosure SEC source: 0001127602-23-014679 · form4.xml · derivative · entry 1 NABEL ELIZABETH G · CIK 0001619929 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,601 Underlying: Common Stock · 4,601 shares Expires 2033-05-03 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.